Phio Pharmaceuticals Corp. — Investor Relations & Filings
Filings indexed
857
across all filing types
Latest filing
2026-04-08
Regulatory Filings
Country
US
United States of America
Listing
US
PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing immuno-oncology therapeutics. The company's proprietary INTASYL technology is a self-delivering RNA interference (RNAi) platform that utilizes small interfering RNA (siRNA) to silence genes. This process is designed to enhance the ability of the body's immune cells to recognize and kill cancer cells. Phio's development pipeline is focused on treatments for solid tumors, with key initiatives in cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its lead clinical compound is PH-762.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-04-08 | English | |
| 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-03-30 | English | |
| Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company | 2026-02-23 | English | |
| 8-K - PHIO PHARMACEUTICALS CORP. (0001533040) (Filer) | 2026-02-18 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-02-10 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
14 filings
| |||||
| 33847768 | 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-04-08 | English | ||
| 33087316 | 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-03-30 | English | ||
| 32828377 | Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company | 2026-02-23 | English | ||
| 32893507 | 8-K - PHIO PHARMACEUTICALS CORP. (0001533040) (Filer) | 2026-02-18 | English | ||
| 30422182 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 19423381 | 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-02-10 | English | ||
| 30422106 | 4 Filing | 2026-02-06 | English | ||
| 30422104 | 4 Filing | 2026-02-06 | English | ||
| 30422074 | 4 Filing | 2026-02-06 | English | ||
| 30422072 | 4 Filing | 2026-02-06 | English | ||
| 30422071 | 4 Filing | 2026-02-06 | English | ||
| 30422066 | 4 Filing | 2026-02-06 | English | ||
| 30422205 | 8-K Filing | 2026-01-20 | English | ||
| 12500297 | Director's Dealing 2026 | 2026-01-02 | English | ||
|
2025
1 filing
| |||||
| 12500300 | Director's Dealing 2025 | 2025-12-29 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Apontis Pharma AG
Develops and markets fixed-dose combination drugs (Single P…
|
APPH | DE | Manufacturing |
|
Appili Therapeutics Inc.
Biopharmaceutical company developing novel medicines for in…
|
APLI | CA | Manufacturing |
|
Applied BioCode
Develops and manufactures high-throughput multiplex molecul…
|
6598 | TW | Manufacturing |
|
Applied Therapeutics, Inc.
Clinical-stage biopharma developing novel drugs for rare me…
|
APLT | US | Manufacturing |
|
Aprogen Biologics Inc.
Develops and manufactures novel biologics and biosimilar an…
|
003060 | KR | Manufacturing |
|
Aprogen, Inc
Develops and manufactures biologic medicines, including bio…
|
007460 | KR | Manufacturing |
|
Aptabio Therapeutics Inc.
Develops drugs for intractable diseases by regulating oxida…
|
293780 | KR | Manufacturing |
|
Aptamer Sciences Inc
Clinical-stage company developing aptamer-based therapeutic…
|
291650 | KR | Manufacturing |
|
Aptorum Group Ltd
Clinical-stage biopharma developing therapeutics for oncolo…
|
APM | US | Manufacturing |
|
Aptus Pharma Limited
Develops and manufactures cardiovascular, metabolic, and ga…
|
544529 | IN | Manufacturing |
Phio Pharmaceuticals Corp. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35112/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35112 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35112 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35112 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35112}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Phio Pharmaceuticals Corp. (id: 35112)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.